Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Efficacy of systemic temozolomide-activated phage-targeted gene therapy in human glioblastoma.

Przystal JM, Waramit S, Pranjol MZI, Yan W, Chu G, Chongchai A, Samarth G, Olaciregui NG, Tabatabai G, Carcaboso AM, Aboagye EO, Suwan K, Hajitou A.

EMBO Mol Med. 2019 Apr;11(4). pii: e8492. doi: 10.15252/emmm.201708492.

2.
3.

Selective Inhibition of Histone Deacetylation in Melanoma Increases Targeted Gene Delivery by a Bacteriophage Viral Vector.

Campbell S, Suwan K, Waramit S, Aboagye EO, Hajitou A.

Cancers (Basel). 2018 Apr 21;10(4). pii: E125. doi: 10.3390/cancers10040125.

4.

The natural dietary genistein boosts bacteriophage-mediated cancer cell killing by improving phage-targeted tumor cell transduction.

Tsafa E, Al-Bahrani M, Bentayebi K, Przystal J, Suwan K, Hajitou A.

Oncotarget. 2016 Aug 9;7(32):52135-52149. doi: 10.18632/oncotarget.10662.

5.

Dual systemic tumor targeting with ligand-directed phage and Grp78 promoter induces tumor regression.

Kia A, Przystal JM, Nianiaris N, Mazarakis ND, Mintz PJ, Hajitou A.

Mol Cancer Ther. 2012 Dec;11(12):2566-77. doi: 10.1158/1535-7163.MCT-12-0587. Epub 2012 Oct 10.

6.

Proteasome inhibition in cancer is associated with enhanced tumor targeting by the adeno-associated virus/phage.

Przystal JM, Umukoro E, Stoneham CA, Yata T, O'Neill K, Syed N, Hajitou A.

Mol Oncol. 2013 Feb;7(1):55-66. doi: 10.1016/j.molonc.2012.08.001. Epub 2012 Aug 21.

7.

Targeted systemic gene therapy and molecular imaging of cancer contribution of the vascular-targeted AAVP vector.

Hajitou A.

Adv Genet. 2010;69:65-82. doi: 10.1016/S0065-2660(10)69008-6. Review.

PMID:
20807602
8.

Clathrin-mediated endocytosis and subsequent endo-lysosomal trafficking of adeno-associated virus/phage.

Stoneham CA, Hollinshead M, Hajitou A.

J Biol Chem. 2012 Oct 19;287(43):35849-59. doi: 10.1074/jbc.M112.369389. Epub 2012 Aug 22.

9.

Design and construction of targeted AAVP vectors for mammalian cell transduction.

Hajitou A, Rangel R, Trepel M, Soghomonyan S, Gelovani JG, Alauddin MM, Pasqualini R, Arap W.

Nat Protoc. 2007;2(3):523-31.

PMID:
17406616
10.

Intracranial AAV-IFN-β gene therapy eliminates invasive xenograft glioblastoma and improves survival in orthotopic syngeneic murine model.

GuhaSarkar D, Neiswender J, Su Q, Gao G, Sena-Esteves M.

Mol Oncol. 2017 Feb;11(2):180-193. doi: 10.1002/1878-0261.12020. Epub 2017 Jan 18.

11.

A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme.

Kim SS, Rait A, Kim E, Pirollo KF, Chang EH.

Nanomedicine. 2015 Feb;11(2):301-11. doi: 10.1016/j.nano.2014.09.005. Epub 2014 Sep 18.

12.

Targeted molecular-genetic imaging and ligand-directed therapy in aggressive variant prostate cancer.

Ferrara F, Staquicini DI, Driessen WHP, D'Angelo S, Dobroff AS, Barry M, Lomo LC, Staquicini FI, Cardó-Vila M, Soghomonyan S, Alauddin MM, Flores LG 2nd, Arap MA, Lauer RC, Mathew P, Efstathiou E, Aparicio AM, Troncoso P, Navone NM, Logothetis CJ, Marchiò S, Gelovani JG, Sidman RL, Pasqualini R, Arap W.

Proc Natl Acad Sci U S A. 2016 Nov 8;113(45):12786-12791. doi: 10.1073/pnas.1615400113. Epub 2016 Oct 24.

13.

Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.

Wang H, Cai S, Bailey BJ, Reza Saadatzadeh M, Ding J, Tonsing-Carter E, Georgiadis TM, Zachary Gunter T, Long EC, Minto RE, Gordon KR, Sen SE, Cai W, Eitel JA, Waning DL, Bringman LR, Wells CD, Murray ME, Sarkaria JN, Gelbert LM, Jones DR, Cohen-Gadol AA, Mayo LD, Shannon HE, Pollok KE.

J Neurosurg. 2017 Feb;126(2):446-459. doi: 10.3171/2016.1.JNS152513. Epub 2016 May 13.

14.

Encapsulation of temozolomide in a tumor-targeting nanocomplex enhances anti-cancer efficacy and reduces toxicity in a mouse model of glioblastoma.

Kim SS, Rait A, Kim E, DeMarco J, Pirollo KF, Chang EH.

Cancer Lett. 2015 Dec 1;369(1):250-8. doi: 10.1016/j.canlet.2015.08.022. Epub 2015 Sep 2.

15.

Modulation of extracellular matrix in cancer is associated with enhanced tumor cell targeting by bacteriophage vectors.

Yata T, Lee EL, Suwan K, Syed N, Asavarut P, Hajitou A.

Mol Cancer. 2015 Jun 3;14:110. doi: 10.1186/s12943-015-0383-4.

16.

Towards a transcriptome-based theranostic platform for unfavorable breast cancer phenotypes.

Dobroff AS, D'Angelo S, Eckhardt BL, Ferrara F, Staquicini DI, Cardó-Vila M, Staquicini FI, Nunes DN, Kim K, Driessen WHP, Hajitou A, Lomo LC, Barry M, Krishnamurthy S, Sahin A, Woodward WA, Prossnitz ER, Anderson RL, Dias-Neto E, Brown-Glaberman UA, Royce ME, Ueno NT, Cristofanilli M, Hortobagyi GN, Marchiò S, Gelovani JG, Sidman RL, Arap W, Pasqualini R.

Proc Natl Acad Sci U S A. 2016 Nov 8;113(45):12780-12785. doi: 10.1073/pnas.1615288113. Epub 2016 Oct 24.

17.

Chloroquine enhances temozolomide cytotoxicity in malignant gliomas by blocking autophagy.

Golden EB, Cho HY, Jahanian A, Hofman FM, Louie SG, Schönthal AH, Chen TC.

Neurosurg Focus. 2014 Dec;37(6):E12. doi: 10.3171/2014.9.FOCUS14504.

PMID:
25434381
18.

miR-20a mediates temozolomide-resistance in glioblastoma cells via negatively regulating LRIG1 expression.

Wei J, Qi X, Zhan Q, Zhou D, Yan Q, Wang Y, Mo L, Wan Y, Xie D, Xie J, Yang S.

Biomed Pharmacother. 2015 Apr;71:112-8. doi: 10.1016/j.biopha.2015.01.026. Epub 2015 Feb 7. Erratum in: Biomed Pharmacother. 2016 Dec;84:1440-1441.

PMID:
25960225
19.

Tumor vasculature-targeted delivery of tumor necrosis factor-alpha.

Tandle A, Hanna E, Lorang D, Hajitou A, Moya CA, Pasqualini R, Arap W, Adem A, Starker E, Hewitt S, Libutti SK.

Cancer. 2009 Jan 1;115(1):128-39. doi: 10.1002/cncr.24001.

20.

20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.

Chen Z, Wei X, Shen L, Zhu H, Zheng X.

Cancer Sci. 2019 Jan;110(1):389-400. doi: 10.1111/cas.13881. Epub 2018 Dec 14.

Supplemental Content

Support Center